Risk management strategy for preventing the reduced treatment effectiveness from the position of drug interactions and polypharmacy in patients with coronary heart disease

Авторы

DOI:

https://doi.org/10.3897/rrpharmacology.6.60164

Аннотация

Introduction: In modern clinical practice, various drug combinations are widely used, especially in cardiological pa­tients. The existing clinical recommendations necessitate using organ protective agents, especially with a patient having a comorbid pathology and with an ineffective monotherapy. In some cases, drug interaction decreases the effectiveness of pharmacotherapy and increases the risk of developing adverse events (AE).

The purpose of the study was to analyze the modern pharmacotherapy of patients with coronary heart disease (CHD), identify polypharmacy of treatment, evaluate its significance for the treatment process, and determine ways to solve the problem of using a multi-component system of pharmacotherapy risk management.

Materials and methods: The study involved 156 patients with CHD, among whom 39 received more than 8 drugs at a time.

Results and discussion: In these patients, the evaluation of drug interactions revealed 580 variants (48 were danger­ous, 428 – significant, 104 – insignificant). The administration of a therapy to comorbid patients, taking into account possible changes in the activity of cytochrome P450 isoenzymes, is one of the promising ways to improve the safety of a combined pharmacotherapy.

Conclusion: It was revealed that with a mutated cytochrome P450 most of processes of drug biotransformation occurs. And there is a greater risk of developing AE against the background of polypragmasia in polymorbid patients, which makes it possible to individually adjust the dose of beta-blockers, thus affecting the frequency of their development. The choice of management measures should be determined considering all the areas of personalized medicine, includ­ing pharmacogenetic predictors, pharmacoepidemiological data, pharmacoeconomic effectiveness, the development of adverse reactions, polypragmasia, and medical and social risk factors.

Ключевые слова:

polypharmacy, drug interaction, cardiovascular therapy, complication

Вклад авторов

Anna A. Gruzdeva, Yaroslavl State Medical University; Regional State Healthcare Institution, District Hospital № 1 of Kostroma District

Candidate of Medical Sciences.

Alexander L. Khokhlov, Yaroslavl State Medical University

Doctor Habil. of Medical Sciences, Professor, Corresponding Member of the Russian Academy of Sciences.

Mikhail V. Ilyin, Yaroslavl State Medical University

Doctor Habil. of Medical Sciences, Associate Professor.

Загрузки

Опубликован

30.12.2020

Как цитировать

Gruzdeva AA, Khokhlov AL, Ilyin MV (2020) Risk management strategy for preventing the reduced treatment effectiveness from the position of drug interactions and polypharmacy in patients with coronary heart disease. Research Results in Pharmacology 6(4): 85–92. https://doi.org/10.3897/rrpharmacology.6.60164

Выпуск

Раздел

Обзорная статья

Наиболее читаемые статьи этого автора (авторов)